Real-world assessment of ipi-nivo in anti-PD-(L)-1 refractory Merkel Cell Carcinoma
2022
Real world evaluation of ipilimumab/nivolumab in PD-1/PDL-1 refractory MCC
Details:
Event: Multicenter Merkel Cell Interest Group Meeting, Boston Massachusetts
This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement